ClinicalTrials.gg
CompletedNCT02791230Updated Feb 3, 2025Results posted

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

A Phase 3 interventional study of Tafamidis in Transthyretin (TTR) Amyloid Cardiomyopathy, sponsored by Pfizer. Completed at 80 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,733
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Amyloid Neuropathies, Familial with a site in United States — 23 open to participants now, 26 under way, 4 of them phase 3. Amyloid Neuropathies, Familial · United States.

Enrollment
2nd of 38
1,733 · median 53
Started
2016
with 1 other
Phase 3
14 of 58
2 open now
Registered
12th of 58
by date
Lead sponsor
3 of 58
Pfizer

Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, this one is the 2nd largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2016, is one of 14 in phase 3, and was the 12th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

23 of the 58 studies in Amyloid Neuropathies, Familial with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Amyloid Neuropathies, Familial with a site in United States, or all of them as a file.
02

Study summary

Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy

Read the detailed description

Global Phase 3, open label long term extension safety study designed to obtain additional safety data for tafamidis meglumine 20 mg and 80 mg (or tafamidis 61 mg where available), and to continue to provide enrolled subjects with tafamidis for up to 60 months, or until subject has access to tafamidis for ATTR CM via prescription, whichever occurs first.

03

Conditions studied

  • Transthyretin (TTR) Amyloid Cardiomyopathy

Keywords

  • amyloidosis
  • amyloid
  • transthyretin
  • TTR
  • ATTR-CM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort A: Completion of 30 months of study treatment on Pfizer Protocol B3461028

Cohort B: Patients in specific countries diagnosed with ATTR-CM who did not previously participate in Pfizer Study B3461028

Exclusion criteria

Exclusion Criteria:

-Liver and/or heart transplant, or implanted cardiac mechanical assist device

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,733 participants (actual)

Study arms

  • Experimental
    Tafamidis

    Active treatment - 61 mg or if not available, tafamidis meglumine 80 mg

    Drug: Tafamidis

Interventions

  • Soft gel capsules administered once a day for 60 months

06

What researchers measure

Primary outcomes

  1. Time to All-Cause Mortality: Cohort A

    Time to all-cause mortality was calculated from first dose of randomized treatment in parent study (B3461028) to all-cause mortality events. All-cause mortality events included deaths, heart transplants and cardiac mechanical assist devices implantation treated as death. Treated participants from the parent study who discontinued prior to the start of this study were also included in this analysis as planned. Data from participants who dropped out for a liver-only transplantation were handled in the same manner as the data from all other censored participants. Censored participants were participants who completed study or discontinued from the study (including discontinued by sponsor or participants withdrew, or discontinued due to Adverse event (AE), or alive at the time of analysis. Kaplan Meier method was used for analysis. Therefore, this analysis was based on the pooled dose groups, as per the statistical analysis plan (SAP).

    Time frame: From first dose of randomized treatment in parent study (B3461028) up to 28 days post last dose of study treatment in current extension study (B3461045), [approximately up to 91 months]

  2. Number of Participants With All-Cause Mortality Events: Cohort B

    All-cause mortality included all participants who had discontinue for transplantation (i.e. heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. Data from participants who dropped out for a liver-only transplantation were handled in the same manner as the data from all other censored participants. Censored participants were participants who completed study or discontinued from the study (including discontinued by sponsor or participants withdrew, or discontinued due to AE), or alive at the time of analysis. Kaplan Meier method was used for analysis.

    Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)

  3. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received investigational product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment or worsened during the treatment period relative to the pretreatment state. AEs included both SAEs and all Non-SAEs. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; considered an important medical event.

    Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)

Other outcomes

  1. Time to Cardiovascular-Related Mortality Events: Cohort A

    Time to cardiovascular-related mortality was calculated from first dose of randomized treatment in B3461028 . Participants who discontinued for transplantation (that is heart transplantation and combined heart and liver transplantation) or for implantation of cardiac mechanical assist device were treated as a death. Treated participants from the parent study who discontinued prior to the start of this study were also included in this analysis as planned. Kaplan-Meier method was used. Therefore, this analysis was based on the pooled dose groups, as per the SAP.

    Time frame: From first dose of randomized treatment in parent study (B3461028) up to 28 days post last dose of study treatment in current extension study (B3461045), [approximately up to 91 months]

  2. Number of Participants With Cardiovascular Related Mortality Events: Cohort B

    Deaths adjudicated as cardiovascular-related and indeterminate were reported. Cardiovascular-related mortality events included deaths, heart transplants and cardiac mechanical assist devices implantation treated as death. Cardiovascular relatedness was based on clinical judgement.

    Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)

  3. Mean Annualized Rate of All Cause Hospitalizations

    Mean annual rate of all cause hospitalization was calculated for each participant as the participant's number of all cause hospitalizations divided by this participant's duration on study in years. Hospitalization was defined as any initial admission (even less than 24 hours) in a hospital or equivalent healthcare facility or any prolongation of an existing admission. Only all cause hospitalizations where the participant was admitted to a hospital during the current extension study were included in this analysis. Any hospitalizations prior to randomization date were not included.

    Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)

  4. Mean Annualized Rate of Cardiovascular (CV)-Related Hospitalizations

    Mean annual rate of CV related hospitalization was calculated for each participant as the participant's number of CV related hospitalizations divided by this participant's duration on study in years. CV-related hospitalizations included hospitalizations due to heart failure, arrhythmia, myocardial infarction, stroke, and other cardiovascular-related events. Hospitalization was defined as any initial admission (even less than 24 hours) in a hospital or equivalent healthcare facility or any prolongation of an existing admission. Admission also included transfer within the hospital to an acute/intensive care unit (example: from the psychiatric wing to a medical floor, medical floor to a coronary care unit, or neurological floor to a tuberculosis unit).

    Time frame: B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)

  5. Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Scores at Months 12, 30, 42, 60 and 90: Cohort A

    KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-clinical summary score was calculated as mean of the following domains- physical limitation and total symptoms and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as least square (LS) mean.

    Time frame: B3461028: Baseline (Day 1, pre-dose), Months 12, 30; B3461045: Months 42, 60 and 90 (time points were relative to Day 1 from B3461028; 42, 60 and 90 Months were 12, 30 and 60 Months of B3461045)

  6. Change From Baseline in KCCQ Overall Score at Months 12, 30, 42, 60, 90: Cohort A

    KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-overall score was calculated as mean of the following domains- physical limitation, total symptoms (average of symptom frequency \& symptom burden), quality of life, social limitation and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as LS mean.

    Time frame: B3461028: Baseline (Day 1, pre-dose), Months 12, 30; B3461045: Months 42, 60 and 90 (time points were relative to Day 1 from B3461028; 42, 60 and 90 Months were 12, 30 and 60 Months of B3461045)

  7. Change From Baseline in KCCQ Total Symptom Score at Months 12, 30, 42, 60 and 90: Cohort A

    KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ Total Symptoms score was calculated as mean of the following domains- symptom frequency and symptom burden and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as LS mean.

    Time frame: B3461028: Baseline (Day 1, pre-dose), Months 12, 30; B3461045: Months 42, 60 and 90 (time points were relative to Day 1 from B3461028; 42, 60 and 90 Months were 12, 30 and 60 Months of B3461045)

  8. Change From Baseline in KCCQ Clinical Summary Scores at Months 12, 30 and 54: Cohort B

    KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-clinical summary score was calculated as mean of the following domains- physical limitation and total symptoms and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.

    Time frame: B3461045: Baseline (Day 1, pre-dose), Months 12, 30 and 54

  9. Change From Baseline in KCCQ Overall Score at Months 12, 30 and 54: Cohort B

    KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-overall score was calculated as mean of the following domains- physical limitation, total symptoms (average of symptom frequency \& symptom burden), quality of life, social limitation and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.

    Time frame: B3461045: Baseline (Day 1, pre-dose), Months 12, 30 and 54

  10. Change From Baseline in KCCQ Total Symptom Score at Months 12, 30 and 54: Cohort B

    KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ Total Symptoms score was calculated as mean of the following domains- symptom frequency and symptom burden and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.

    Time frame: B3461045: Baseline (Day 1, pre-dose), Months 12, 30 and 54

  11. Number of Participants With Shift From Baseline in New York Heart Association (NYHA) Classification at Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

    NYHA classification: Class I: Participants with cardiovascular disease (CVD) but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain; Class II: Participants with CVD resulting in slight limitation of physical activity and were comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or angina pain; Class III: participants with CVD resulting in marked limitation of physical activity and were comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain; Class IV: participants with CVD resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity was undertaken, discomfort was increased.

    Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

  12. Change From Baseline in Body Mass Index (BMI) at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

    BMI was calculated as: body weight in kilogram (kg) divided by (/) square of body height measurement in meters square (m\^2).

    Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

  13. Change From Baseline in Modified Body Mass Index (mBMI) at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

    Modified (m)BMI of participants was calculated to determine if there was any gastrointestinal involvement in participants. The mBMI was calculated by multiplying BMI by serum albumin concentration gram/liter (g/L).

    Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

  14. Change From Baseline in Troponin I Concentration at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

    Troponin I is the cardiac markers. Higher level of the marker was indicative of heart damage. It was measure in nanogram per milliliter (ng/mL). Safety analysis population included all participants (Cohorts A and B) who were enrolled in this study and taken at least 1 dose of study medication.

    Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

  15. Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

    NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. It was measure in picomole per liter (pmole/L). Higher level of the marker was indicative of heart damage. Safety analysis population included all participants (Cohorts A and B) who were enrolled in this study and taken at least 1 dose of study medication.

    Time frame: B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

07

Results

Posted Feb 3, 2025
Limitations and caveats
For analyses in current extension study for Cohort A based on CMA set, it combined data from participants in parent study B3461028, including participants who died, discontinued in parent study B3461028, or did not enroll into the current extension study B3461045.Data for these participants is used only in few planned outcomes and these participants do not reflect in any other section of this record. For reference, results for B3461028 can be found at ClinicalTrails.gov with NCT ID: NCT01994889.

Participant flow

The study consisted of two cohorts: Cohort A and B. Cohort A: Participants diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) who completed 30 months of participation in parent study \[B3461028 (NCT01994889)\] were enrolled in this current extension study (B3461045 \[NCT02791230\]). Cohort B: Participants diagnosed with ATTR-CM who did not participate in parent study B3461028 study were enrolled in this extension study.

Participant flow — Overall Study
MilestoneCohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Started170821481
Treated170821476
Completed8431988
Not completed8651493
Withdrew: Adverse event10966
Withdrew: Death3825184
Withdrew: Lack of efficacy103
Withdrew: Lost to follow-up0010
Withdrew: Failure to meet randomization criteria3215
Withdrew: Medication error without associated adverse event011
Withdrew: Study sites terminated by sponsor105
Withdrew: Other9128
Withdrew: Protocol violation004
Withdrew: Withdrawal by subject2413172
Withdrew: Enrolled but not treated005

Outcome measures

PrimaryTime to All-Cause Mortality: Cohort A

Time to all-cause mortality was calculated from first dose of randomized treatment in parent study (B3461028) to all-cause mortality events. All-cause mortality events included deaths, heart transplants and cardiac mechanical assist devices implantation treated as death. Treated participants from the parent study who discontinued prior to the start of this study were also included in this analysis as planned. Data from participants who dropped out for a liver-only transplantation were handled in the same manner as the data from all other censored participants. Censored participants were participants who completed study or discontinued from the study (including discontinued by sponsor or participants withdrew, or discontinued due to Adverse event (AE), or alive at the time of analysis. Kaplan Meier method was used for analysis. Therefore, this analysis was based on the pooled dose groups, as per the statistical analysis plan (SAP).

Time frame:
From first dose of randomized treatment in parent study (B3461028) up to 28 days post last dose of study treatment in current extension study (B3461045), [approximately up to 91 months]
Reported as:
Median · Months
Time to All-Cause Mortality: Cohort A
MonthsCohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study)Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study)
Time to All-Cause Mortality: Cohort A58.7 (50.3 to 68.4)35.8 (29.7 to 41.1)
Statistical analysis
  • Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study) vs Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study) · Cox proportional hazards model · p = 0.0001 · Hazard ratio (hr): 0.6202 · 95% CI 0.4865 to 0.7906Hazard ratio from a Cox proportional hazards model with treatment, Transthyretin (TTR) genotype (variant and wild-type) and New York Heart Association (NYHA) baseline classification (NYHA Classes I and II combined and NYHA Class III) in the model.
PrimaryNumber of Participants With All-Cause Mortality Events: Cohort B

All-cause mortality included all participants who had discontinue for transplantation (i.e. heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. Data from participants who dropped out for a liver-only transplantation were handled in the same manner as the data from all other censored participants. Censored participants were participants who completed study or discontinued from the study (including discontinued by sponsor or participants withdrew, or discontinued due to AE), or alive at the time of analysis. Kaplan Meier method was used for analysis.

Time frame:
B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Reported as:
Count of participants · Participants
Number of Participants With All-Cause Mortality Events: Cohort B
ParticipantsCohort B: Tafamidis (Only in Extension Study)
Number of Participants With All-Cause Mortality Events: Cohort B345
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received investigational product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment or worsened during the treatment period relative to the pretreatment state. AEs included both SAEs and all Non-SAEs. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; considered an important medical event.

Time frame:
B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs)
ParticipantsCohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Number of Participants With Treatment-Emergent Adverse Events (AEs)168791294
Other pre-specifiedTime to Cardiovascular-Related Mortality Events: Cohort A

Time to cardiovascular-related mortality was calculated from first dose of randomized treatment in B3461028 . Participants who discontinued for transplantation (that is heart transplantation and combined heart and liver transplantation) or for implantation of cardiac mechanical assist device were treated as a death. Treated participants from the parent study who discontinued prior to the start of this study were also included in this analysis as planned. Kaplan-Meier method was used. Therefore, this analysis was based on the pooled dose groups, as per the SAP.

Time frame:
From first dose of randomized treatment in parent study (B3461028) up to 28 days post last dose of study treatment in current extension study (B3461045), [approximately up to 91 months]
Reported as:
Median · Months
Time to Cardiovascular-Related Mortality Events: Cohort A
MonthsCohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study)Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study)
Time to Cardiovascular-Related Mortality Events: Cohort A70.2 (63.4 to 88.8)40.8 (34.1 to 50.7)
Statistical analysis
  • Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study) vs Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study) · Cox Proportional Hazards model · p = 0.0005 · Hazard ratio: 0.6133 · 95% CI 0.4666 to 0.8062Hazard ratio from a Cox proportional hazards model with treatment, TTR genotype (variant and wild-type) and NYHA baseline classification (NYHA Classes I and II combined and NYHA Class III) in the model.
Other pre-specifiedNumber of Participants With Cardiovascular Related Mortality Events: Cohort B

Deaths adjudicated as cardiovascular-related and indeterminate were reported. Cardiovascular-related mortality events included deaths, heart transplants and cardiac mechanical assist devices implantation treated as death. Cardiovascular relatedness was based on clinical judgement.

Time frame:
B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Reported as:
Count of participants · Participants
Number of Participants With Cardiovascular Related Mortality Events: Cohort B
ParticipantsCohort B: Tafamidis (Only in Extension Study)
Number of Participants With Cardiovascular Related Mortality Events: Cohort B204
Other pre-specifiedMean Annualized Rate of All Cause Hospitalizations

Mean annual rate of all cause hospitalization was calculated for each participant as the participant's number of all cause hospitalizations divided by this participant's duration on study in years. Hospitalization was defined as any initial admission (even less than 24 hours) in a hospital or equivalent healthcare facility or any prolongation of an existing admission. Only all cause hospitalizations where the participant was admitted to a hospital during the current extension study were included in this analysis. Any hospitalizations prior to randomization date were not included.

Time frame:
B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Reported as:
Mean · Hospitalization/year
Mean Annualized Rate of All Cause Hospitalizations
Hospitalization/yearCohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Mean Annualized Rate of All Cause Hospitalizations1.67 ± 5.8301.84 ± 2.2750.96 ± 5.117
Other pre-specifiedMean Annualized Rate of Cardiovascular (CV)-Related Hospitalizations

Mean annual rate of CV related hospitalization was calculated for each participant as the participant's number of CV related hospitalizations divided by this participant's duration on study in years. CV-related hospitalizations included hospitalizations due to heart failure, arrhythmia, myocardial infarction, stroke, and other cardiovascular-related events. Hospitalization was defined as any initial admission (even less than 24 hours) in a hospital or equivalent healthcare facility or any prolongation of an existing admission. Admission also included transfer within the hospital to an acute/intensive care unit (example: from the psychiatric wing to a medical floor, medical floor to a coronary care unit, or neurological floor to a tuberculosis unit).

Time frame:
B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months)
Reported as:
Mean · CV related hospitalization/year
Mean Annualized Rate of Cardiovascular (CV)-Related Hospitalizations
CV related hospitalization/yearCohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Mean Annualized Rate of Cardiovascular (CV)-Related Hospitalizations1.09 ± 5.4091.14 ± 1.8990.50 ± 1.567
Other pre-specifiedChange From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Scores at Months 12, 30, 42, 60 and 90: Cohort A

KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-clinical summary score was calculated as mean of the following domains- physical limitation and total symptoms and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as least square (LS) mean.

Time frame:
B3461028: Baseline (Day 1, pre-dose), Months 12, 30; B3461045: Months 42, 60 and 90 (time points were relative to Day 1 from B3461028; 42, 60 and 90 Months were 12, 30 and 60 Months of B3461045)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Scores at Months 12, 30, 42, 60 and 90: Cohort A
Units on a scaleCohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study)Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study)
Change at Month 12-3.17 ± 1.016-10.2 ± 1.316
Change at Month 30-7.41 ± 1.185-19.9 ± 1.999
Change at Month 42-11.2 ± 1.483-25.4 ± 2.143
Change at Month 60-11.8 ± 1.756-25.1 ± 3.287
Change at Month 90-17.4 ± 2.758-56.9 ± 1.868
Other pre-specifiedChange From Baseline in KCCQ Overall Score at Months 12, 30, 42, 60, 90: Cohort A

KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-overall score was calculated as mean of the following domains- physical limitation, total symptoms (average of symptom frequency \& symptom burden), quality of life, social limitation and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as LS mean.

Time frame:
B3461028: Baseline (Day 1, pre-dose), Months 12, 30; B3461045: Months 42, 60 and 90 (time points were relative to Day 1 from B3461028; 42, 60 and 90 Months were 12, 30 and 60 Months of B3461045)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in KCCQ Overall Score at Months 12, 30, 42, 60, 90: Cohort A
Units on a scaleCohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study)Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study)
Change at Month 12-1.97 ± 1.131-9.69 ± 1.428
Change at Month 30-6.07 ± 1.399-19.5 ± 1.908
Change at Month 42-8.81 ± 1.470-24.0 ± 2.114
Change at Month 60-8.56 ± 1.646-24.5 ± 3.020
Change at Month 90-18.1 ± 2.617-52.6 ± 1.791
Other pre-specifiedChange From Baseline in KCCQ Total Symptom Score at Months 12, 30, 42, 60 and 90: Cohort A

KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ Total Symptoms score was calculated as mean of the following domains- symptom frequency and symptom burden and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as LS mean.

Time frame:
B3461028: Baseline (Day 1, pre-dose), Months 12, 30; B3461045: Months 42, 60 and 90 (time points were relative to Day 1 from B3461028; 42, 60 and 90 Months were 12, 30 and 60 Months of B3461045)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in KCCQ Total Symptom Score at Months 12, 30, 42, 60 and 90: Cohort A
Units on a scaleCohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study)Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study)
Change at Month 12-2.90 ± 1.182-10.3 ± 1.494
Change at Month 30-5.92 ± 1.279-18.7 ± 2.276
Change at Month 42-9.29 ± 1.699-22.5 ± 2.237
Change at Month 60-8.94 ± 1.858-19.0 ± 3.693
Change at Month 90-16.4 ± 2.654-56.0 ± 1.958
Other pre-specifiedChange From Baseline in KCCQ Clinical Summary Scores at Months 12, 30 and 54: Cohort B

KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-clinical summary score was calculated as mean of the following domains- physical limitation and total symptoms and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.

Time frame:
B3461045: Baseline (Day 1, pre-dose), Months 12, 30 and 54
Reported as:
Mean · Units on a scale
Change From Baseline in KCCQ Clinical Summary Scores at Months 12, 30 and 54: Cohort B
Units on a scaleCohort B: Tafamidis (Only in Extension Study)
Change at Month 12-0.242 ± 17.7032
Change at Month 30-3.086 ± 20.4276
Change at Month 54-3.988 ± 18.7931
Other pre-specifiedChange From Baseline in KCCQ Overall Score at Months 12, 30 and 54: Cohort B

KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ-overall score was calculated as mean of the following domains- physical limitation, total symptoms (average of symptom frequency \& symptom burden), quality of life, social limitation and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.

Time frame:
B3461045: Baseline (Day 1, pre-dose), Months 12, 30 and 54
Reported as:
Mean · Units on a scale
Change From Baseline in KCCQ Overall Score at Months 12, 30 and 54: Cohort B
Units on a scaleCohort B: Tafamidis (Only in Extension Study)
Change at Month 120.443 ± 18.2575
Change at Month 30-1.378 ± 20.9437
Change at Month 54-2.093 ± 19.5085
Other pre-specifiedChange From Baseline in KCCQ Total Symptom Score at Months 12, 30 and 54: Cohort B

KCCQ: 23-item, self-administered questionnaire that assesses health status and health-related quality of life in participants with heart failure. KCCQ quantifies 8 domains: physical limitations, symptom stability, symptom frequency, symptom burden, total symptom (mean of symptom frequency and symptom burden), self-efficacy, quality of life and social limitations). Scores were generated for each domain and scaled from 0 (worst) to 100 (best possible status). KCCQ Total Symptoms score was calculated as mean of the following domains- symptom frequency and symptom burden and transformed to a single score which ranged from 0 (worst) -100 (best possible status), higher scores = better health status. Data for change from baseline was reported as mean.

Time frame:
B3461045: Baseline (Day 1, pre-dose), Months 12, 30 and 54
Reported as:
Mean · Units on a scale
Change From Baseline in KCCQ Total Symptom Score at Months 12, 30 and 54: Cohort B
Units on a scaleCohort B: Tafamidis (Only in Extension Study)
Change at Month 120.738 ± 19.1549
Change at Month 30-1.112 ± 20.7952
Change at Month 54-1.885 ± 19.4433
Other pre-specifiedNumber of Participants With Shift From Baseline in New York Heart Association (NYHA) Classification at Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

NYHA classification: Class I: Participants with cardiovascular disease (CVD) but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain; Class II: Participants with CVD resulting in slight limitation of physical activity and were comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or angina pain; Class III: participants with CVD resulting in marked limitation of physical activity and were comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain; Class IV: participants with CVD resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity was undertaken, discomfort was increased.

Time frame:
B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in New York Heart Association (NYHA) Classification at Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
ParticipantsCohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Month 6 — Class I (Baseline) to Class I134132
Month 6 — Class I (Baseline) to Class II4270
Month 6 — Class I (Baseline) to Class III008
Month 6 — Class I (Baseline) to Class IV000
Month 6 — Class II (Baseline) to Class I7060
Month 6 — Class II (Baseline) to Class II6520542
Month 6 — Class II (Baseline) to Class III112100
Month 6 — Class II (Baseline) to Class IV001
Month 6 — Class III (Baseline) to Class I104
Month 6 — Class III (Baseline) to Class II17988
Month 6 — Class III (Baseline) to Class III3424226
Month 6 — Class III (Baseline) to Class IV002
Month 6 — Class IV (Baseline) to Class I001
Month 6 — Class IV (Baseline) to Class II112
Month 6 — Class IV (Baseline) to Class III1310
Month 6 — Class IV (Baseline) to Class IV113
Month 12 — Class I (Baseline) to Class I10494
Month 12 — Class I (Baseline) to Class II5060
Month 12 — Class I (Baseline) to Class III103
Month 12 — Class I (Baseline) to Class IV000
Month 12 — Class II (Baseline) to Class I6050
Month 12 — Class II (Baseline) to Class II6316371
Month 12 — Class II (Baseline) to Class III10167
Month 12 — Class II (Baseline) to Class IV101
Month 12 — Class III (Baseline) to Class I301
Month 12 — Class III (Baseline) to Class II12967
Month 12 — Class III (Baseline) to Class III3123127
Month 12 — Class III (Baseline) to Class IV000
Month 12 — Class IV (Baseline) to Class I000
Month 12 — Class IV (Baseline) to Class II001
Month 12 — Class IV (Baseline) to Class III017
Month 12 — Class IV (Baseline) to Class IV001
Month 18 — Class I (Baseline) to Class I5464
Month 18 — Class I (Baseline) to Class II3045
Month 18 — Class I (Baseline) to Class III003
Month 18 — Class I (Baseline) to Class IV000
Month 18 — Class II (Baseline) to Class I8041
Month 18 — Class II (Baseline) to Class II4915259
Month 18 — Class II (Baseline) to Class III9161
Month 18 — Class II (Baseline) to Class IV001
Month 18 — Class III (Baseline) to Class I205
Month 18 — Class III (Baseline) to Class II19657
Month 18 — Class III (Baseline) to Class III241970
Month 18 — Class III (Baseline) to Class IV000
Month 18 — Class IV (Baseline) to Class I200
Month 18 — Class IV (Baseline) to Class II002
Month 18 — Class IV (Baseline) to Class III223
Month 18 — Class IV (Baseline) to Class IV000
Month 24 — Class I (Baseline) to Class I4442
Month 24 — Class I (Baseline) to Class II4140
Month 24 — Class I (Baseline) to Class III210
Month 24 — Class I (Baseline) to Class IV000
Month 24 — Class II (Baseline) to Class I8031
Month 24 — Class II (Baseline) to Class II4912191
Month 24 — Class II (Baseline) to Class III3042
Month 24 — Class II (Baseline) to Class IV000
Month 24 — Class III (Baseline) to Class I403
Month 24 — Class III (Baseline) to Class II11834
Month 24 — Class III (Baseline) to Class III171446
Month 24 — Class III (Baseline) to Class IV000
Month 24 — Class IV (Baseline) to Class I000
Month 24 — Class IV (Baseline) to Class II101
Month 24 — Class IV (Baseline) to Class III204
Month 24 — Class IV (Baseline) to Class IV000
Month 30 — Class I (Baseline) to Class I1127
Month 30 — Class I (Baseline) to Class II1032
Month 30 — Class I (Baseline) to Class III001
Month 30 — Class I (Baseline) to Class IV000
Month 30 — Class II (Baseline) to Class I5126
Month 30 — Class II (Baseline) to Class II277129
Month 30 — Class II (Baseline) to Class III2124
Month 30 — Class II (Baseline) to Class IV000
Month 30 — Class III (Baseline) to Class I402
Month 30 — Class III (Baseline) to Class II14422
Month 30 — Class III (Baseline) to Class III10924
Month 30 — Class III (Baseline) to Class IV000
Month 30 — Class IV (Baseline) to Class I000
Month 30 — Class IV (Baseline) to Class II002
Month 30 — Class IV (Baseline) to Class III002
Month 30 — Class IV (Baseline) to Class IV000
Month 36 — Class I (Baseline) to Class I1221
Month 36 — Class I (Baseline) to Class II4018
Month 36 — Class I (Baseline) to Class III000
Month 36 — Class I (Baseline) to Class IV000
Month 36 — Class II (Baseline) to Class I3019
Month 36 — Class II (Baseline) to Class II197101
Month 36 — Class II (Baseline) to Class III2125
Month 36 — Class II (Baseline) to Class IV000
Month 36 — Class III (Baseline) to Class I103
Month 36 — Class III (Baseline) to Class II5221
Month 36 — Class III (Baseline) to Class III7414
Month 36 — Class III (Baseline) to Class IV000
Month 36 — Class IV (Baseline) to Class I000
Month 36 — Class IV (Baseline) to Class II101
Month 36 — Class IV (Baseline) to Class III010
Month 36 — Class IV (Baseline) to Class IV000
Month 42 — Class I (Baseline) to Class I0016
Month 42 — Class I (Baseline) to Class II3111
Month 42 — Class I (Baseline) to Class III001
Month 42 — Class I (Baseline) to Class IV000
Month 42 — Class II (Baseline) to Class I419
Month 42 — Class II (Baseline) to Class II14477
Month 42 — Class II (Baseline) to Class III2016
Month 42 — Class II (Baseline) to Class IV000
Month 42 — Class III (Baseline) to Class I101
Month 42 — Class III (Baseline) to Class II3120
Month 42 — Class III (Baseline) to Class III4112
Month 42 — Class III (Baseline) to Class IV000
Month 42 — Class IV (Baseline) to Class I000
Month 42 — Class IV (Baseline) to Class II000
Month 42 — Class IV (Baseline) to Class III000
Month 42 — Class IV (Baseline) to Class IV000
Month 48 — Class I (Baseline) to Class I006
Month 48 — Class I (Baseline) to Class II208
Month 48 — Class I (Baseline) to Class III000
Month 48 — Class I (Baseline) to Class IV000
Month 48 — Class II (Baseline) to Class I212
Month 48 — Class II (Baseline) to Class II12454
Month 48 — Class II (Baseline) to Class III207
Month 48 — Class II (Baseline) to Class IV000
Month 48 — Class III (Baseline) to Class I200
Month 48 — Class III (Baseline) to Class II318
Month 48 — Class III (Baseline) to Class III4113
Month 48 — Class III (Baseline) to Class IV000
Month 48 — Class IV (Baseline) to Class I000
Month 48 — Class IV (Baseline) to Class II000
Month 48 — Class IV (Baseline) to Class III001
Month 48 — Class IV (Baseline) to Class IV000
Month 54 — Class I (Baseline) to Class I001
Month 54 — Class I (Baseline) to Class II003
Month 54 — Class I (Baseline) to Class III000
Month 54 — Class I (Baseline) to Class IV000
Month 54 — Class II (Baseline) to Class I001
Month 54 — Class II (Baseline) to Class II7322
Month 54 — Class II (Baseline) to Class III206
Month 54 — Class II (Baseline) to Class IV000
Month 54 — Class III (Baseline) to Class I300
Month 54 — Class III (Baseline) to Class II314
Month 54 — Class III (Baseline) to Class III307
Month 54 — Class III (Baseline) to Class IV000
Month 54 — Class IV (Baseline) to Class I000
Month 54 — Class IV (Baseline) to Class II000
Month 54 — Class IV (Baseline) to Class III000
Month 54 — Class IV (Baseline) to Class IV000
Month 60 — Class I (Baseline) to Class I00—
Month 60 — Class I (Baseline) to Class II00—
Month 60 — Class I (Baseline) to Class III00—
Month 60 — Class I (Baseline) to Class IV00—
Month 60 — Class II (Baseline) to Class I00—
Month 60 — Class II (Baseline) to Class II40—
Month 60 — Class II (Baseline) to Class III20—
Month 60 — Class II (Baseline) to Class IV00—
Month 60 — Class III (Baseline) to Class I10—
Month 60 — Class III (Baseline) to Class II12—
Month 60 — Class III (Baseline) to Class III10—
Month 60 — Class III (Baseline) to Class IV00—
Month 60 — Class IV (Baseline) to Class I00—
Month 60 — Class IV (Baseline) to Class II00—
Month 60 — Class IV (Baseline) to Class III00—
Month 60 — Class IV (Baseline) to Class IV00—
Other pre-specifiedChange From Baseline in Body Mass Index (BMI) at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

BMI was calculated as: body weight in kilogram (kg) divided by (/) square of body height measurement in meters square (m\^2).

Time frame:
B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Reported as:
Mean · kg/m^2
Change From Baseline in Body Mass Index (BMI) at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
kg/m^2Cohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Change at Month 6-0.07 ± 0.873-0.27 ± 0.900-0.24 ± 1.234
Change at Month 12-0.21 ± 1.212-0.40 ± 1.440-0.20 ± 1.552
Change at Month 18-0.38 ± 1.442-0.85 ± 1.502-0.30 ± 1.956
Change at Month 24-0.36 ± 1.407-0.78 ± 1.668-0.43 ± 1.747
Change at Month 30-0.71 ± 1.423-1.28 ± 1.814-0.41 ± 1.802
Change at Month 36-1.18 ± 2.200-0.49 ± 1.852-0.69 ± 1.730
Change at Month 42-0.91 ± 1.402-0.11 ± 1.523-0.74 ± 1.827
Change at Month 48-1.14 ± 1.480-0.01 ± 1.927-0.83 ± 1.732
Change at Month 54-1.03 ± 1.716-1.54 ± 0.528-1.24 ± 1.942
Change at Month 60-0.93 ± 2.102-1.62 ± 0.834—
Other pre-specifiedChange From Baseline in Modified Body Mass Index (mBMI) at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

Modified (m)BMI of participants was calculated to determine if there was any gastrointestinal involvement in participants. The mBMI was calculated by multiplying BMI by serum albumin concentration gram/liter (g/L).

Time frame:
B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Reported as:
Mean · (kg/m^2) *(g/L)
Change From Baseline in Modified Body Mass Index (mBMI) at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
(kg/m^2) *(g/L)Cohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Change at Month 6-2.96 ± 36.046-10.91 ± 36.338-8.51 ± 51.329
Change at Month 12-7.42 ± 49.840-16.09 ± 57.882-6.17 ± 66.094
Change at Month 18-15.46 ± 60.361-35.46 ± 63.390-10.08 ± 85.605
Change at Month 24-15.07 ± 58.706-32.33 ± 71.104-15.81 ± 74.009
Change at Month 30-29.31 ± 61.003-52.81 ± 78.705-15.70 ± 79.724
Change at Month 36-49.46 ± 98.257-17.81 ± 80.327-24.66 ± 74.366
Change at Month 42-36.32 ± 58.1301.59 ± 69.701-28.06 ± 78.987
Change at Month 48-46.43 ± 62.39414.05 ± 83.969-32.91 ± 71.745
Change at Month 54-41.98 ± 74.883-52.80 ± 14.562-51.15 ± 79.618
Change at Month 60-38.90 ± 92.253-41.20 ± NA—
Other pre-specifiedChange From Baseline in Troponin I Concentration at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

Troponin I is the cardiac markers. Higher level of the marker was indicative of heart damage. It was measure in nanogram per milliliter (ng/mL). Safety analysis population included all participants (Cohorts A and B) who were enrolled in this study and taken at least 1 dose of study medication.

Time frame:
B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Reported as:
Mean · ng/mL
Change From Baseline in Troponin I Concentration at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
ng/mLCohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Change at Month 6——0.012 ± 0.1706
Change at Month 120.035 ± 0.39770.037 ± 0.08530.009 ± 0.0893
Change at Month 180.040 ± NA—-0.007 ± 0.0786
Change at Month 240.000 ± 0.05660.033 ± 0.0306-0.031 ± 0.2031
Change at Month 300.022 ± 0.15990.100 ± 0.1728-0.033 ± 0.2055
Change at Month 360.009 ± 0.05790.018 ± 0.1057-0.034 ± 0.1913
Change at Month 42-0.002 ± 0.0795-0.047 ± 0.0755-0.021 ± 0.2484
Change at Month 480.016 ± 0.0795-0.067 ± 0.2040-0.100 ± 0.0000
Change at Month 54-0.033 ± 0.0792-0.363 ± 0.6080—
Change at Month 60-0.040 ± 0.04140.035 ± 0.0354—
Other pre-specifiedChange From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. It was measure in picomole per liter (pmole/L). Higher level of the marker was indicative of heart damage. Safety analysis population included all participants (Cohorts A and B) who were enrolled in this study and taken at least 1 dose of study medication.

Time frame:
B3461045: Baseline (Day 1, pre-dose), Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Reported as:
Mean · pmole/L
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Months 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
pmole/LCohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Change at Month 6——24.820 ± 171.2075
Change at Month 1231.117 ± 220.9279127.973 ± 226.772732.686 ± 180.4921
Change at Month 18226.442 ± NA—71.582 ± 329.5411
Change at Month 24131.334 ± 119.5258256.442 ± 101.807392.899 ± 320.6054
Change at Month 30159.596 ± 404.8483417.682 ± 597.9224149.049 ± 320.8814
Change at Month 36322.963 ± 215.1605420.196 ± 251.844688.895 ± 227.7375
Change at Month 42419.034 ± 315.6436324.211 ± 173.6652191.318 ± 482.3582
Change at Month 48492.154 ± 387.4700400.571 ± 228.4343264.566 ± 78.7059
Change at Month 54405.887 ± 457.6349340.082 ± 190.6412—
Change at Month 60392.363 ± 271.2883314.184 ± 274.6756—

Adverse events

Collected over B3461045: From first dose of treatment up to 28 days post last dose of study treatment (approximately up to 61 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: Tafamidis (Parent and Extension Study)45/170 (26.5%)132/170 (77.6%)152/170 (89.4%)
Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)33/82 (40.2%)64/82 (78%)76/82 (92.7%)
Cohort B: Tafamidis (Only in Extension Study)203/1,476 (13.8%)736/1,476 (49.9%)1,023/1,476 (69.3%)
Most frequent serious events
Showing 10 of 566
Most frequent serious events
EventCohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
Cardiac failureCardiac disorders30/17017/82169/1476
Cardiac failure congestiveCardiac disorders17/17014/8252/1476
Acute kidney injuryRenal and urinary disorders16/17013/8234/1476
Cardiac failure acuteCardiac disorders13/17010/8248/1476
PneumoniaInfections and infestations12/1709/8239/1476
Atrial fibrillationCardiac disorders11/1708/8262/1476
Ventricular tachycardiaCardiac disorders3/1706/8217/1476
CellulitisInfections and infestations8/1705/8218/1476
FallInjury, poisoning and procedural complications10/1705/8225/1476
DehydrationMetabolism and nutrition disorders0/1705/827/1476
Most frequent other events
Showing 10 of 72
Most frequent other events
EventCohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)
FallInjury, poisoning and procedural complications41/17034/82146/1476
Pleural effusionRespiratory, thoracic and mediastinal disorders23/17024/8258/1476
HypotensionVascular disorders14/17020/8270/1476
Oedema peripheralGeneral disorders26/17018/82100/1476
CoughRespiratory, thoracic and mediastinal disorders29/17018/8281/1476
DyspnoeaRespiratory, thoracic and mediastinal disorders31/17018/82110/1476
Atrial fibrillationCardiac disorders32/17017/82150/1476
HypokalaemiaMetabolism and nutrition disorders23/17017/8261/1476
Urinary tract infectionInfections and infestations18/17016/8275/1476
ConstipationGastrointestinal disorders18/17015/82117/1476

Baseline characteristics

The safety analysis population consisted of all participants (Cohorts A and B) who were enrolled in this study and who had taken at least one dose of study treatment.

Age, Continuous
Age, Continuous(Years)Cohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)Total
Mean76.73 ± 6.7576.41 ± 6.4776.51 ± 7.7576.52 ± 7.60
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)Total
Female138165186
Male1577413111542
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)Total
Hispanic or Latino513743
Not Hispanic or Latino1648114331678
Unknown or Not Reported1067
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: Tafamidis (Parent and Extension Study)Cohort A: Placebo (Parent Study)/Tafamidis (Extension Study)Cohort B: Tafamidis (Only in Extension Study)Total
American Indian or Alaska Native0000
Asian956680
Native Hawaiian or Other Pacific Islander0000
Black or African American155139159
White1447212521468
More than one race0000
Unknown or Not Reported201921
08

Study locations

80 sites
  • The Kirklin Clinic of UAB Hospital
    Birmingham, Alabama 35233, United States
  • Cardiovascular Clinical Trials Unit (CCTU)
    Birmingham, Alabama 35294, United States
  • University Hospital, University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • California Heart Center
    Beverly Hills, California 90211, United States
  • Cedars-Sinai Medical Care Foundation
    Beverly Hills, California 90211, United States
  • Altman Clinical Translational Research Institute
    La Jolla, California 92037, United States
  • University of California, San Diego
    La Jolla, California 92037, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California, San Diego Medical Center - Hillcrest
    San Diego, California 92103, United States
  • Center Adv Lab Medicine
    San Diego, California 92121, United States
  • UCSF Ambulatory Care Center
    San Francisco, California 94143, United States
  • University of California
    San Francisco, California 94143, United States
  • UCSF Cardiovascular Care and Prevention Center
    San Francisco, California 94158, United States
  • Stanford University Hospital and Clinics
    Stanford, California 94305, United States
  • Sylvester at Deerfield Beach
    Deerfield Beach, Florida 33136, United States
  • University of Miami Hospital & Clinics/Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • University of Maryland, Baltimore
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Boston Medical Center Investigational Pharmacy
    Boston, Massachusetts 02118, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • Michigan Medicine,University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic Hospital-Rochester
    Rochester, Minnesota 55902, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Center for Advanced Cardiac Care
    New York, New York 10032, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • OHSU Center for Health and Healing
    Portland, Oregon 97239, United States
  • OHSU Research Pharmacy Services
    Portland, Oregon 97239, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt Univ. Med. Ctr
    Nashville, Tennessee 37232, United States
  • Huntsman Cancer Hospital
    Salt Lake City, Utah 84112, United States
  • University of Utah Hospitals & Clinics
    Salt Lake City, Utah 84132, United States
  • University of Utah, Division of Cardiovascular Medicine
    Salt Lake City, Utah 84132, United States
  • Instituto Cardiovascular de Buenos Aires
    Ciudad Autónoma de Buenos Aires, C1428ART, Argentina
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Eastern Health (Box Hill Hospital)
    Box Hill, Victoria 3128, Australia
  • UZ Leuven
    Leuven, 3000, Belgium
  • Hospital Universitário Clementino Fraga Filho (UFRJ)
    Rio de Janeiro, RJ 21941-913, Brazil
  • University of Calgary/Foothills Medical Centre
    Calgary, Alberta T2N 4Z6, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
  • Fakultni nemocnice u sv. Anny v Brne
    Brno, 656 91, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • Institut klinicke a experimentalni mediciny
    Praha 4, 140 21, Czechia
  • Hopital de La Timone
    Marseille, CAN 13005, France
  • CHU Henri Mondor
    Creteil, 94010, France
  • Hôpital De La Timone
    Marseille, 13385, France
  • Hopital Bichat
    Paris, 75018, France
  • CHU de Rennes - Hopital Pontchaillou
    Rennes, 35033, France
  • CHU de Rennes - Hôpital Pontchaillou
    Rennes, 35033, France
  • CHU de Toulouse - Hôpital Rangueil
    Toulouse, 31059, France
  • Medical University of Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Clinical Trial Pharmacy
    Hong Kong, Hong Kong
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliero-Universitaria Careggi
    Firenze, 50134, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Kurume University Hospital
    Kurume-shi, Fukuoka 830-0011, Japan
  • Kumamoto University Hospital
    Kumamoto-city, Kumamoto 860-8556, Japan
  • Shinshu University Hospital
    Nagano, 390-8621, Japan
  • University Medical Center Groningen
    Groningen, 9713 GZ, Netherlands
  • Unidad de Insuficiencia Cardiaca Avanzada y Transplante Cardiaco
    A Coruna, LA Coruna 15006, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Skellefteå Lasarett
    Skellefteå, 931 86, Sweden
  • Akademiska Sjukhuset
    Uppsala, 751 85, Sweden
  • Investigational Drug Services
    Taipei, 100, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
  • Barts Health NHS Trust, St Bartholomew's Hospital
    London, EC1A 7BE, United Kingdom
09

References and documents

Publications

  • Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20. PubMed 34923848 ↗
  • Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021 Feb;23(2):277-285. doi: 10.1002/ejhf.2027. Epub 2020 Nov 12. PubMed 33070419 ↗
  • Li B, Alvir J, Stewart M. Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial. Cardiol Ther. 2020 Dec;9(2):535-540. doi: 10.1007/s40119-020-00179-2. Epub 2020 Jun 10. PubMed 32524297 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Oct 2023, 88 months.

Results were first posted in Feb 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2016
First posted
Jun 6, 2016
StartActual
Jun 13, 2016
Primary completionActual
Oct 26, 2023
CompletionActual
Nov 2, 2023
Results first posted
Feb 3, 2025
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02791230
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 6, 2016
Start date
Jun 13, 2016
Primary completion
Oct 26, 2023
Completion
Nov 2, 2023
Results posted
Feb 3, 2025
Last update
Feb 3, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion